CHENGDU,
China, Dec. 19, 2024 /PRNewswire/ -- BGM Group
Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin
Zhanchang, Chairman of the Board of Directors of BGM Group and
Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the
sales team to visit their long-term strategic partner, Jointown
Pharmaceutical Group. They were warmly welcomed by Mr. Liu Shulin, one of the founders and Honorary
Vice Chairman of Jointown, along with Vice Chairman Mr.
Liu Dengpan and other senior
executives. The two sides held a cordial, productive meeting,
further consolidating and deepening their strategic partnership.
They also signed a strategic cooperation agreement for Qilianshan
Pharmaceutical's licorice fluid extract and Gandixin (Compound
Licorice Tablets) series products.
Jointown Pharmaceutical Group, as a leading enterprise in
China's pharmaceutical industry
with the most extensive sales network, focuses on Western medicine,
traditional Chinese medicine, and medical devices. It is committed
to providing medical institutions, wholesale companies, and retail
pharmacies with pharmaceutical products, logistics, and other
value-added services. Meanwhile, BGM Group has demonstrated
exceptional performance in the research, development, production,
and operation of its "Qilianshan" brand pharmaceutical products.
The long-standing partnership between the two companies stems from
their outstanding achievements in their respective fields and a
shared commitment to development philosophies.
Over the years, BGM Group and Jointown have demonstrated a high
degree of synergy in several areas. First, in product research,
development, production, and sales, Qilianshan Pharmaceutical, a
subsidiary of BGM Group, leverages its strong R&D capabilities
and advanced production technologies under the "Qilianshan" brand.
Combined with Jointown's comprehensive sales network and logistics
distribution system, BGM's products have gained widespread
recognition and acceptance in domestic and international markets.
Second, BGM Group's rigorous quality testing system ensures product
safety and quality. Both companies share a commitment to customer
service excellence, offering comprehensive after-sales support and
prioritizing consumer satisfaction. Lastly, in market expansion and
brand building, the two companies maintain close collaboration,
enhancing the influence of both the BGM and Jointown brands.
During the meeting, the two parties engaged in in-depth
discussions on market demand, quality control, and sales channel
expansion for licorice-based products. They agreed that as the
pharmaceutical industry continues to evolve, consumer demand for
high-quality, high-efficiency pharmaceutical products will grow
significantly. Both companies are dedicated to driving product
innovation and quality improvement to meet the diverse needs of the
market.
In the presence of both teams, BGM Group and Jointown signed a
strategic cooperation agreement for the licorice fluid extract and
Gandixin (Compound Licorice Tablets) series products. This
agreement marks a new milestone in their collaboration in the
pharmaceutical sector, particularly in licorice-based products,
with injecting strong momentum into their future development. Both
parties reaffirmed their commitment to maintaining a close
partnership and contributing to the prosperity and advancement of
the pharmaceutical industry.
This successful meeting between BGM Group and Jointown
Pharmaceutical Group not only further solidified their strategic
partnership but also paved the way for broader opportunities for
future cooperation. Together, BGM Group and Jointown are poised to
create an even brighter chapter in the pharmaceutical industry.
Attendees of the meeting included Mr. Gong Li, Vice President of
Jointown; Ms. Zhang Meiqin, General Manager of the Active
Pharmaceutical Ingredients Division; Ms. Fu Qian, Deputy General
Manager of Jiuxin Clinic under Jointown's Health Group; Mr.
Liu Hui, Deputy General Manager of
Quanqing Health; Mr. Wang Xiaoyan, Deputy General Manager of the
Group Procurement Division; and Ms. Liu Yingmei, Sales Director of
BGM Group.
About BGM Group Ltd
BGM Group Ltd,headquartered
in Chengdu, China, is an
innovative company dedicated to the fields of biopharmaceuticals,
bio-extraction, and medical health. Our current product range
includes oxytetracycline APIs, licorice preparations, and crude
heparin sodium. The oxytetracycline API not only provides raw
materials for pharmaceutical companies to produce human antibiotics
but also supports the global breeding and livestock industries to
ensure the safety of poultry and seafood. The crude heparin sodium,
after processing by downstream companies, is transformed into
refined heparin sodium and heparin sodium injection solutions,
which are major anticoagulants. Licorice preparations, such as
compound licorice lozenges, are used as cough suppressants and
supplied to retail pharmacies. For more information, visit the
Company's website at: https://www.bgmgroupltd.com/
Forward-looking Statements
This news release contains
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and as defined in the
U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will", "expects", "anticipates", "future", "intends", "plans",
"believes", "estimates", "target", "going forward", "outlook" and
similar statements. Such statements are based upon management's
current expectations and current market and operating conditions
and relate to events that involve known or unknown risks,
uncertainties and other factors, all of which are difficult to
predict and many of which are beyond the Company's control, which
may cause the Company's actual results, performance or achievements
to differ materially from those in the forward-looking statements.
Further information regarding these and other risks, uncertainties
or factors is included in the Company's filings with the U.S.
Securities and Exchange Commission. The Company does not undertake
any obligation to update any forward-looking statement as a result
of new information, future events or otherwise, except as required
under law.
For investor and media inquiries, please contact:
info@qiliancorp.com
View original
content:https://www.prnewswire.com/news-releases/bgm-group-and-jointown-deepen-cooperation-ushering-in-a-new-era-of-pharmaceutical-development-302336104.html
SOURCE BGM Group Ltd
